Exchange: NASDAQ·Updated 07:54 AM EDT
News
all
press releases
What to Know About This Natera Insider Transaction as Shares Surge to Record Highs
Key PointsA Natera executive sold 3,410 shares for approximately $906,000 on August 3...
Nasdaq News: Markets
More News
A Natera Co-Founder Sold 2,000 Shares From a Spouse's Account. Here's What It Suggests
Key PointsThe transaction involved the sale of 2,000 shares on August 7 for a total value of $641,800...
Nasdaq News: Markets
Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know
Key PointsThe transaction involved 731 shares with an estimated value of $195,901 as of the August 3 transaction date...
Nasdaq News: Markets
A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It
Key PointsThe transactions involved 795 shares sold for an estimated total value of about $216,000...
Nasdaq News: Markets
A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know
Key PointsThe co-founder sold 9,150 shares for a total transaction value of approximately $2.9 million, based on the weighted-average execution price...
Nasdaq News: Markets
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 results and raised FY26 sales guidance. Other big gains include DOCS, QNST, TEAM, CRSR, OABI, PUBM, TWLO, BTG, and ROAD.read more...
Benzinga
Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook
Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue outlook bump.read more...
Benzinga
These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months
Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.
Stocktwits
Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of 0.00% and +14.23%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Natera Q2 Loss Narrows As Revenue Jumps; Raises FY26 Revenue Outlook
(RTTNews) - Natera Inc. (NTRA) on Thursday reported a narrower second-quarter loss as revenue surged 38% on higher testing volumes and pricing improvements. The genetic testing company also raised its full-year 2026 revenue guidance...
Nasdaq News: Markets

Advertisement|Remove ads.